On May 20, 2025, analyst Robert Burns of HC Wainwright & Co. provided an updated assessment on Cogent Biosciences (COGT, Financial). Despite lowering the price target, the firm's 'Buy' rating was upheld, reflecting ongoing confidence in the stock's potential.
Previously, the price target for Cogent Biosciences (COGT, Financial) was set at $14.00 USD. However, this target has been adjusted downward to $12.00 USD. This change represents a 14.29% decrease in the price target compared to the prior forecast.
The rating for Cogent Biosciences (COGT, Financial) remains a 'Buy', indicating that the analyst continues to see positive prospects for the company's future performance. Investors are advised to consider this updated price target in their decision-making processes.
As of the date of this report, Cogent Biosciences (COGT, Financial) continues to be a stock of interest, with the maintained 'Buy' rating suggesting potential growth, despite the adjusted price expectations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Cogent Biosciences Inc (COGT, Financial) is $16.27 with a high estimate of $24.00 and a low estimate of $7.00. The average target implies an upside of 223.19% from the current price of $5.04. More detailed estimate data can be found on the Cogent Biosciences Inc (COGT) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Cogent Biosciences Inc's (COGT, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
